CCR6+ T cells as potential drivers of inflammation in chronic thromboembolic pulmonary hypertension
C Ferreira, T Moura, L Rocha, G Castro, R Silva, E Carvalho, H Pinho, R Batista, L Goncalves, A PaivaAbstract
Introduction
Chronic Thromboembolic Pulmonary Hypertension (CTEPH) is one of the leading causes of severe hypertension, characterized by chronic fibrotic thrombi. Increasing evidence highlights a role for inflammation and immune dysregulation in the pathogenesis of CTEPH; however, it remains unclear whether systemic inflammation contributes directly to chronic thrombus formation and how it influences subsequent vascular remodeling. The aim of this study was to characterize peripheral blood T-lymphocyte subsets in patients with CTEPH
Methods
High-dimensional flow cytometry was employed to profile peripheral T lymphocytes in 23 patients with prevalent CTEPH and 15 age- and sex-matched healthy controls (HC) (Table 1). A total of 288 T-cell subpopulations were identified and analyzed based on detailed phenotypic and functional markers expression.
Results
The main findings in the CTEPH group demonstrated a significant reduction in total lymphocytes compared with HC, including CD4+ T cells, CD8+ T cells, CD4⁻CD8⁻ T cells, and follicular CD195⁻CD196⁻ subsets. Notably, an expansion of naïve CD4+ T-cell compartments was observed, whereas CD8+ T cells exhibited increased proportions of effector memory and effector subsets. Both CD4+ and CD8+ T cells showed a marked enrichment in the CCR6 phenotype.
Analysis of activation markers further revealed increased frequencies of CD8+CCR5+CCR6+ T cells, activated CD8+follicular T cells, and CD4+CD8+ activated T cells. Importantly, within the CD25+ population, a significant expansion of CCR6-expressing cells was detected in both CD4+ and CD8+ T-cell subsets. This pattern supports an ongoing inflammatory immune response.
Conclusion
These findings reveal a profound remodeling of the T-lymphocyte compartment in patients with CTEPH. We observed a redistribution of CD4+ and CD8+ memory subsets, together with enrichment of CCR6-expressing populations. CCR6 is a phenotypic marker of Th17/Tc17 cells, which are typically associated with IL-17 production and the promotion of chronic inflammatory responses. Collectively, these results support a potential role for CCR6+ T cell–driven immunopathology in CTEPH. Further studies are warranted to clarify the functional contribution of these cells and to explore whether therapeutic strategies targeting CCR6+ T cell pathways could represent a novel approach in CTEPH management.For image description, please refer to the figure legend and surrounding text.For image description, please refer to the figure legend and surrounding text.